GVS advice on levodopa/carbidopa/entacapon intestinal gel (Lecigon®) for the treatment of Parkinson's disease
The National Health Care Institute has completed its assessment whether levodopa/carbidopa/entacapon intestinal gel (Lecigon®) can be included in the Medicine Reimbursement System (GVS). Lecigon® is registered for the treatment of advanced Parkinson's disease. The National Health Care Institute advises the Minister to include Lecigon® intestinal gel in the GVS only if a price adjustment for the cartridge can ensure a cost-neutral application.
Indication for which reimbursement is requested
Lecigon® is registered for the treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results. It is available as an intestinal gel in a cartridge (=47 ml) containing 940 mg levodopa, 235 mg carbidopa monohydrate and 940 mg entacapone.
National Health Care Institute's advice
The fixed dose combination Lecigon® is not interchangeable with any products in the GVS and is therefore in principle eligible for placement on List 1B. The National Health Care Institute recommends the Minister to include Lecigon® intestinal gel in the GVS only if a price adjustment for the cartridge can ensure a cost-neutral application.